TAFA4 and cervical cancer: In addition, post hoc analyses of a large screening trial by De Strooper et al19 and Dick et al20 have shown that the long‐term risk of hrHPV positive, FAM19A4/miR124‐2 methylation‐negative women is similar or better for cervical cancer and ≥CIN3 endpoints compared to a negative cytology test.